Base follow-up during active surveillance on a strict protocol including DRE (at least once yearly), PSA (at least once every 6 months) and repeated biopsy every 2 to 3 years. #ProstateCancer #EAUguidelines uroweb.org/guidelines/pro…

Il corso di alta formazione, che si è tenuto a Roma, è stato fonte di apprendimento e di riflessione per tutti i partecipanti e anche per i relatori. Grazie a tutti Luca Cindolo Cosimo De Nunzio Vincenzo Li Marzi Antonio L. Pastore

🔬 New Podcast: Explore the impact of a multi-disciplinary virtual genetics tumor board on prostate cancer care. Over 90% found discussions useful & technology easy. Tune in for expert insights! 🎙️#ProstateCancerCare Stacy Loeb, MD

Exciting study results on #Rezum therapy show it significantly improves urinary symptoms in patients with benign prostatic enlargement. Reduced prostate volume and better flow rates are clear wins.🏥📈 #ProstateHealth #Urology" More On: rdcu.be/dF3vh

🌟 Exciting news! #ChatGPT can guide patients following a prostate cancer diagnosis. With clinically sound advice and high understandability, AI proves to be a valuable companion for patient education. 📚🤖 More: doi.org/10.1038/s41391… #ProstateCancer #HealthTech #PatientCare

Do you want to know more about biochemical recurrence in #prostatecancer? Discover key insights and essential guidelines in our latest #UrologyCheatSheet! Thanks to J&J Innovative Medicine España for making this resource possible. Stay informed! ROC Clinic

🚨 New Study Alert! 🚨 Over the past 15 years, the use of pre-biopsy MRI for prostate cancer detection has skyrocketed 📈 — from 0.5% in 2007 to 35.5% in 2022. The findings highlight not only the clinical shift towards MRI-guided approaches but also significant disparities in

🚨 New findings on 4Kscore and Active Surveillance! 🚨 In a study of 166 men with prostate cancer on an MRI-based protocol, baseline 4Kscore predicted grade progression at confirmatory biopsy. 📊 Men with 4Kscore ≥20% had significantly higher risks of progression. Stay

Napoli Santa Maria La Nova 26-28 Sep 2024 A wonderful location for an amazing congress thanks for the great organization and hospitality Giovanni Di Lauro, Paolo Fedelini and Ciro Imbimbo, a great success

🚨 Big News🚨 This Top 5 Most Cited article in Prostate Cancer and Prostatic Diseases 🌟 dives into real-world metastatic castration-resistant prostate cancer (mCRPC): 💡 78% received life-prolonging therapy ⚕️ 💡 Median survival: 25.6 months after mCRPC ⏳ 👉 Highlights major

🎉✨ Happy New Year! ✨🎉 A heartfelt thank you to our amazing authors, dedicated readers, brilliant editors, and tireless reviewers. 📝📚 Your contributions make our journal thrive! Here's to another year of groundbreaking discoveries in prostate cancer and prostatic diseases.

Case report of a seminal vesicle schwannoma involving prostate and bladder: diagnostic pathway and management. pubmed.ncbi.nlm.nih.gov/40007564/

🔬 Racial differences in #mCRPC genomics unveiled! African American tumors show higher MYC & lower inflammatory pathways 🧬🔥 Same outcomes, but distinct biology—diversity in trials is a must! 🌍 ➡️doi.org/10.1038/s41391…

Prostate cancer session at #urooncojourney25 from relevant communications to clinical practice with 🇮🇹 experts of #prostatecancer. Alberto Briganti Filippo Alongi Enrico Finazzi Agrò and Orazio Caffo. Cosimo De Nunzio Sciarra Urology Andrea Tubaro Società Italiana di Urologia SIUrO

📢 Big news! Prostate Cancer and Prostatic Diseases has reached a new Impact Factor of 5.8! A strong recognition of the quality and relevance of our research in the field of urology. Thank you to our authors, reviewers, and readers! #Urology #ProstateCancer #ImpactFactor

Incredible work, Cosimo De Nunzio and team!!! Highest impact factor ever for Prostate Cancer and Prostatic Diseases !!!

#ThrowbackThursday 🧠 Can nomograms beat active surveillance (AS) criteria? PRIAS 🔍 shows the best balance of sensitivity & specificity vs Kattan & Truong nomograms in selecting low-risk organ-confined #ProstateCancer 🧬 ➡️ doi.org/10.1038/pcan.2…

Cosimo De Nunzio Prostate Cancer and Prostatic Diseases Congratulations Cosimo De Nunzio & all Editorial team!

#ThrowbackThursdays 🚹 Battling #BPH? Rezūm therapy delivers: 📉 17% prostate volume shrink 💨 Faster flow rates 🛑 90% off meds 🧑‍⚕️ Proven effective in-office Would you recommend it? 86% say YES! 🔗doi.org/10.1038/s41391…

🆕 New in Eur Urol – In Press! Does prior chemotherapy response predict second-line outcomes in advanced urothelial cancer? Post hoc analysis of KEYNOTE-045 shows pembrolizumab improves survival & response rates regardless of prior chemo response. 🔗 buff.ly/MVngSen